Pope Appeals to Lebanese Crowds to Heal Their Crisis-Hit Nation

By

-

December 2, 2025

Pope urges crowds in Lebanon to fix troubled country — Pope Leo XIV was in Lebanon as part of his first overseas trip since his election as pontiff

Beirut at Dawn: A Pope, a City, and a Fragile Hope

The Mediterranean sun had barely cleared the skyline when the waterfront of Beirut came alive with flags, umbrellas and a kind of brittle joy that only a city accustomed to survival can display.

It was not just any crowd. Tens of thousands—Vatican figures put the number at 150,000—had gathered where modern glass meets Ottoman stone to hear Pope Leo XIV, the first American elected to the papacy, deliver what felt less like a homily and more like a plea: for unity, for justice, for a country that can remember its better angels.

“Cast off the armour of our ethnic and political divisions,” he implored, voice steady under the hot sky. “We must unite our efforts so that this land can return to its glory.”

Scenes from the Waterfront

Students, shopkeepers, priests in cassocks and pensioners in sun hats clustered along the esplanade. They waved tiny Vatican and Lebanese flags in the same palm as their phones. Men and women shielded themselves from the strong Mediterranean light with umbrellas that fluttered like small sails.

“We came before dawn,” said Maroun al‑Mallah, a university volunteer with a tired, hopeful smile. “You can feel it’s a reset. Even if it’s a small one. We’ve had pain after pain—especially after the port blast. Today felt like the city was saying, ‘Maybe we can breathe again.'”

The scene was cinematic: the pope touring the crowd in an enclosed popemobile, stopping to bless, to nod, to meet faces lined with history. The spectacle masked the deeper, quieter weight that every Lebanese soul carried—grief, anger, and an almost scientific exhaustion at promises unkept.

At the Edge of Rubble: Memory and Demand for Justice

Hours before the mass, Pope Leo paused at the scar of Beirut’s 2020 port explosion, laying a wreath at a memorial where photographs of the dead fluttered in the wind. The blast, which killed more than 200 people and caused billions of dollars in damage, still sits in the national consciousness like an unhealed wound.

He walked slowly among survivors and relatives from different faiths, greeting them and offering rosaries tucked in pouches embossed with his coat of arms. A woman who lost her brother reached out to embrace him; she sobbed. He embraced her back.

“He will raise his voice for justice, and we need justice for all the victims,” said Cecile Roukoz, who holds a photograph of her brother like a small, stubborn lantern. “We need someone to say we will not forget.”

When Faith Meets Accountability

The pope’s gesture at the blast site carried symbolic weight. Investigations into the explosion have been repeatedly delayed or obstructed, and no one has been held accountable. For many Lebanese, ritual without remedy feels like salt in an old wound.

“Faith can comfort, but faith cannot replace the work of institutions,” said Dr. Leila Haddad, a Beirut‑based political scientist. “Religious leaders can convene a conversation across sectarian lines, but the hard, technocratic steps—justice, reforms, rebuilding—must follow. Otherwise, this momentum fizzles.”

Lebanon’s Intertwined Crises

It is impossible to paint the pope’s visit without tracing the tangle of crises that brought Lebanon to this moment. The country hosts roughly around a million Syrian and Palestinian refugees, a demographic pressure that has strained public services. Since late 2019, Lebanon has endured a dramatic economic collapse: the local currency has lost much of its value, unemployment has soared, and a large proportion of families now live in multidimensional poverty, measured not just by income but by access to health, education and basic utilities.

Then add the spillover of regional conflict. Last year’s intense exchanges between Israel and the Iran‑aligned Hezbollah left neighborhoods shattered and nerves raw. The threat of renewed hostilities hangs like a low, constant thunder.

2020 Beirut port explosion: over 200 fatalities and billions in damages (official estimates vary)
Refugee presence: approximately one million Syrian and Palestinian refugees in Lebanon, placing strain on infrastructure
Economic collapse: currency depreciation and widespread poverty since late 2019 with long‑lasting social effects

Voices on the Ground

“People ask, ‘What can one visit change?’” said Father Georges Nassar, a Maronite priest whose parish sits in a neighborhood scarred by the explosion. “Change isn’t instant. But when a global religious leader kneels where we knelt and names what’s wrong—corruption, impunity, division—it validates our grief and puts pressure on those who govern.”

“This place has long been a mosaic of religions,” said Nour al‑Amin, a teacher who keeps a small icon in her classroom. “We are Christians, Muslims, Druze. But that diversity has been used as a political lockbox. Can faith free us from that lock? Maybe. But faith has to be paired with courage from politicians and accountability from institutions.”

Experts Weigh In

“Religious leadership can act as a bridge in fragmented societies,” said Dr. Michael Turner, an expert in conflict resolution at an international think tank. “But bridge building must be followed by structural investment—transparent courts, functioning public services, and economic opportunity. Without those, the bridge becomes a spectacle, not a pathway.”

Beyond Beirut: A Mirror for Fragile States

Lebanon’s story resonates well beyond its shores. It is a compact case study of how climate, conflict, economic mismanagement and displacement can conspire to hollow out a country’s institutions. It is a cautionary tale and, to others, a call to empathy.

How do societies stitch themselves back together after trauma? Can religious figures catalyze political redemption? In an age where populism and sectarian politics are surging in many parts of the world, Lebanon asks a question we all must answer: what do we owe each other when the systems we trusted fail?

The pope’s visit did not produce policy roadmaps or immediate indictments. It produced something quieter, and perhaps more crucial: a public naming of pain, a shared mourning, and, for a moment, a crowd that believed—just for a day—that unity was possible.

What Comes Next?

After the crowds dispersed and the last flags were folded, Beirut settled back into the difficult business of daily life. The port’s ruins remain, the economy still teeters, and political rivalries endure. But the visit left behind small sparks: survivors who felt seen, volunteers who felt emboldened, politicians gently nudged by the optics of global attention.

Will those sparks catch? Can rhetoric be translated into reform? Those are questions that will be answered in months and years, in courts and parliaments, in hospital wards and classrooms.

As you read this from wherever you are—city, suburb, or island—ask yourself: when a nation asks for unity, what does solidarity mean in practice? How do you show up? Lebanon’s story is an invitation to consider the hard work of rebuilding trust, brick by brick, prayer by policy.

For now, the memory endures: a waterfront awash in flags, the pope’s steady voice, a woman’s desperate embrace, and a city that refuses to let go of hope. That, perhaps, is the most human thing of all.

Zelensky: There’s a Real Opportunity Now to End the War

By

hanad

-

December 2, 2025

There is a chance to end this war, says Zelensky

I’m ready to reimagine this into a vivid, 800+ word blog piece in a human voice with rich detail, quotes, stats and WordPress-ready HTML — but I don’t actually have the full news content you want rewritten. Could you paste the article or key text here (or give a link)?

Continue

Mangione appears in court at suppression hearing seeking to block evidence

By

hanad

-

December 2, 2025

Mangione appears for suppression of evidence hearing — Luigi Mangione appears for a suppression of evidence hearing in New York (Photo: Steven Hirsch-Pool)

The Man Outside the Midtown Hotel: A Trial That Feels Bigger Than a Crime

On a crisp Manhattan morning, the courthouse at 100 Centre Street hummed like the city itself — part rumor mill, part solemn temple of law. Under a bank of fluorescent lights and just beyond the metal detectors, Luigi Mangione, 27, sat at the defense table in a gray suit patterned with the kind of nondescript care that seems designed to disappear into a crowded room. He said nothing as officers unlatched his handcuffs and the day’s hearings began — hearings that may decide whether crucial pieces of evidence make it to a jury next year.

The charge that brought him here is stark and terrible: the fatal shooting of a UnitedHealthcare executive, Brian Thompson, on a Midtown sidewalk. Mangione was arrested in December 2024 at a McDonald’s in Pennsylvania, recognized from news photos, and accused of a crime that reverberated well beyond the narrow sidewalk where it occurred.

Not just a courtroom drama

This is not only a case about a single act of violence; it’s a flashpoint where anger about health care, the mechanics of policing, and the scope of criminal procedure collide. Outside the courthouse on the first day of hearings, a small crowd had gathered: one demonstrator in a Super Mario Bros. villain costume held a sign reading “When patients die, profits rise,” while a woman wearing a sash that said “Free Luigi” moved through the throng handing out pamphlets. What looked like a carnival tableau underscored something darker — a nation’s simmering frustration about access to care, skyrocketing premiums, and the personal toll of a system many feel is broken.

“People are desperate,” said Maria Gutierrez, a nurse from Queens who came to watch the proceedings. “They see people making billions while their neighbors choose between insulin and rent. It doesn’t excuse violence, but it helps you understand why someone might snap.”

What’s at stake in these hearings

In the next few days, before Judge Gregory Carro, lawyers will argue over the admissibility of what prosecutors say was found in Mangione’s backpack when he was arrested, and whether statements he made while in custody should be used at trial. The items in question — an allegedly 3D-printed firearm, a silencer, electronic devices and journal pages — are the prosecution’s narrative threads tying a suspect to a deed. The defense counters that the search violated Mangione’s rights and that any statements were taken without proper Miranda warnings.

“This is not about clever legal maneuvers; this is about constitutional guardrails,” said Daniel Rios, a defense attorney watching the courtroom. “If the police can circumvent these rules, every weak link in the system becomes a crack in the foundation.”

Arrest in a Pennsylvania McDonald’s

The arrest that followed the shooting reads like a piece of American folklore. Surveillance footage — played in court by a security camera technician — places Mangione inside a McDonald’s in Pennsylvania, eating and waiting, until someone in the restaurant recognized him from the news and alerted authorities. There is a cinematic logic to it: a man brought down not by detectives in a sting, but by the glare of coverage and the watchful eyes of strangers.

Yet even as a prosecutor prepares to stitch the evidence together, defense lawyers insist procedural defects tainted the whole tapestry. At stake in these pretrial hearings is whether the case proceeds with the prosecution’s strongest threads, or whether a jury will see a different picture altogether.

Charges and possible punishments

The scope of the legal jeopardy is substantial. If convicted of murder in the second degree — an intentional killing under New York law — Mangione could face life in prison. He also faces several weapon possession counts and a charge for possessing false identification. In a separate federal case, where prosecutors have signaled an intention to seek the death penalty, he has pleaded not guilty. Trial dates have not been set in either matter.

Murder in the second degree — potential life sentence
Multiple counts of criminal possession of a weapon
Possession of false identification
Separate federal case where the death penalty has been floated by prosecutors

When terror charges were ruled out

Not every arrow in the prosecutor’s quiver stuck. In September, Judge Carro dismissed two terrorism-related counts, finding insufficient evidence that Mangione intended to intimidate health insurance workers or influence government policy. That ruling narrowed the narrative: what remains is framed as a personal and criminal act rather than an explicitly political one.

“That decision reflected the law’s careful boundaries,” said Professor Leah Huang, a constitutional law scholar. “Terrorism counts carry an enormous label. Courts are right to demand clear proof that someone meant to send a political message, not merely to commit a violent act.”

The larger canvas: health care, anger, and a country’s fissures

To appreciate why the case generated headlines and, for some, martyrdom, you have to step back and see the larger American landscape. The United States spends more on health care than any other nation — roughly 18% of GDP in recent years — and per-person expenditures are far higher than in other wealthy democracies. Insurer power and the opaque calculus of premiums and denials have created a climate where frustration sometimes metastasizes into outrage.

“This is not simply about one man and one gun,” said Dr. Amina Farouk, a public health researcher. “It’s about a social contract that many feel is broken. When systems feel indifferent to suffering, some people look for catharsis in extreme ways.”

What a trial could reveal — and what it may not

Courtrooms are blunt instruments for truth: slow, meticulous, rhythmically procedural. They will parse the nuts and bolts of arrest procedure, forensic evidence, and chain-of-custody. They will not, however, settle the broader questions this case touches. They won’t fix a health care system where millions are underinsured, nor will they heal families bereft. What they will do is hold individuals accountable under the law.

As the hearings continue, you might ask yourself: what does justice look like in an era of structural grievance? Can the legal system address individual culpability while also illuminating systemic failure? And if a courtroom focuses our attention briefly on a broken system, who will carry forward the work of repair?

Outside the courthouse, a woman with a “Free Luigi” sash folds a pamphlet into a pocket. A man in a Mario-esque costume argues with a passerby about profits and lives. Inside, lawyers haggle over the admissibility of journal entries and a 3D-printed object. The city, as always, keeps moving — indifferent and intimate, brutal and brilliant.

What happens next will be measured in legal briefs and rulings; in the meantime, the case stands as a mirror. It reflects not just a sliver of criminal conduct but a broader national conversation about rage, responsibility, and the systems that shape both.

Kooxo Hubeysan oo Askari NISA ah ku dishay Magaalada Muqdisho

By

aden

-

December 2, 2025

Dec 02(Jowhar)-Kooxo hubeysan ayaa maanta dil u geysatay Cumar Kalaxay, oo ahaa askari dharcad ah oo ka tirsanaa Ciidanka Nabad Sugidda iyo Sirdoonka Qaranka (NISA). Falka dilka ah ayaa ka dhacay isbaaradii hore ee Saruurka, oo ku taalla degmada Heliwaa ee gobolka Banaadir.

Continue

Wasaaradda Caafimaadka oo Magacaawday Xubnaha Golaha Mihnadlayaasha Caafimaadka Qaranka

By

aden

-

December 2, 2025

Dec 02(Jowhar)-Wasaaradda Caafimaadka iyo Daryeelka Bulshada ayaa maanta shaacisay magacaabista 15 xubnood oo ka mid noqonaya Golaha Mihnadlayaasha Caafimaadka Qaranka (GMQ).

Continue

US and UK unveil tariff-free pharmaceuticals agreement to boost drug trade

By

hanad

-

December 2, 2025

US announces zero-tariff pharmaceutical deal with Britain — The agreement means Britain will be exempted from hefty US tariffs imposed on pharma imports that went into effect on 1 October

A trade-off for cures: How a UK–US deal could reshape medicines, prices and access

On a grey morning in Cambridge, a lab technician in a white coat slid a stack of labelled vials into a freezer and sighed. “We live in a world where a new therapy can mean the difference between work and retirement, between hope and heartbreak,” she said, peeling off her gloves. Outside, cyclists threaded past spires and start-ups; inside, the hum of incubators and the aroma of strong coffee told another story—one of science tethered to markets and politics.

This is the quiet backdrop to a headline-grabbing agreement struck between the United States and the United Kingdom: Britain has agreed to pay more for certain new American medicines in return for a tariff-free path for UK-made pharmaceuticals, drug ingredients and medical devices into the US market.

The deal in plain language

Under the arrangement, the UK will raise the net price it pays for newly introduced US medicines by roughly 25%. In exchange, British-produced drugs and medical technology will be exempted from the sectoral tariffs imposed under Section 232 and from any future tariffs that might flow from Section 301 actions — the two tools the US has used in recent years to impose import levies on national security or trade-distortion grounds.

United States Trade Representative Jamieson Greer described the outcome as “pricing for innovative pharmaceuticals, which will help drive investment and innovation in both countries,” a succinct way of framing an intricate swap of market access for higher domestic payouts.

What changes for patients and the NHS

For people relying on the National Health Service, the most tangible change will not be the tariff language but a shift in how the UK judges the value of new therapies. The National Institute for Health and Care Excellence (NICE), which decides whether the NHS should fund a drug, will raise its quality-adjusted life year (QALY) threshold from about £30,000 to £35,000.

That number — a way of putting a pound value on an extra year of healthy life — can determine whether a cutting-edge but costly cancer drug is available on the NHS or remains an unaffordable option for many patients. Raising the threshold means more drugs may pass the value test and be commissioned, at a greater cost to the public purse.

“Patients want treatments, clinicians want options, and governments need to balance budgets,” said Dr Anita Rao, a health economist at King’s College London. “This adjustment to NICE is a clear signal: the UK is tilting policy to retain pharmaceutical investment and access. Whether that trade-off favours long-term public health remains to be seen.”

Winners, losers and the wider chessboard

From a trade perspective, the UK has secured a valuable concession: exemption from hefty US tariffs that came into force on 1 October. For British drugmakers and device producers — a sector that blends artisan craft with billion-dollar research — tariff relief reduces uncertainty when selling into the world’s largest medicine market.

“These foundations offer an opportunity to secure the UK as a global-leading environment for life sciences,” said a spokesperson for GSK, echoing industry hopes that regulatory warmth will translate into fresh investment. The Association of the British Pharmaceutical Industry (ABPI) also welcomed the deal, calling it a step toward faster patient access to innovative medicines.

Yet this is not simply a feel-good story for the lab coat brigade. The UK has promised to lower the rate of its voluntary rebate scheme — where drugmakers give a slice of sales back to the NHS — to 15% by 2026. So while the headline reads “zero tariffs,” the arithmetic behind medicines is changing: higher per-unit prices for new foreign drugs, a higher QALY threshold, and a planned tapering of clawbacks.

Some industry stocks hardly moved on the news; the UK makes up a small portion of the global revenues for big players. For example, roughly 2% of AstraZeneca’s revenue has historically come from the UK. For multinational firms, the calculus is global, but symbolic shifts in policy can nudge where R&D and manufacturing happen.

Voices from the ground

“My mum was denied a new drug two years ago because it didn’t meet NICE’s price test,” said Saira Khan, whose mother has metastatic breast cancer and lives in Bradford. “If this change means more treatments are available, that’s one thing. But what if it also means the NHS can buy fewer other things? We need transparency.”

At a small pharmacy in Cardiff, pharmacist Tom Evans put it bluntly: “If more drugs are approved, demand on our services will grow. People assume a pill equals a cure, but it can mean more checks, monitoring, side-effect management. That costs staff time.” He shrugged. “Tariffs are invisible to me. I see prescriptions, queues, and letters.”

Bigger themes: sovereignty, inequality and the market for cures

This pact sits at the intersection of several global currents. Since the pandemic and through the fractious post-Brexit trade era, nations have been racing to secure both supply chains and the conditions that make their territory attractive to life-sciences investment. The US has long borne the brunt of higher drug prices; successive administrations have urged allies to lift their payments to narrow the gap.

There is a moral question here. Should the price of innovation be shouldered through higher public spending on drugs — potentially crowding out other services — or through a pricing system that encourages competition and affordability? Is innovation best rewarded through strong market returns, or via public funding and shared risk?

“We have to remember that innovation is global,” said Professor Miguel Alvarez, who studies pharmaceutical markets at the London School of Economics. “Policy nudges, like a raised QALY, change incentives. They might attract clinical trials and manufacturing — jobs, skills, regional growth. But they also risk recalibrating priorities away from prevention and primary care.”

What to watch next

Implementation: Will the NICE threshold rise immediately across the board, and how will that affect ongoing appraisals?
Costs: How much extra will the NHS have to pay annually if more high-cost drugs are approved? (Estimates will vary depending on uptake and the specific therapies involved.)
Investment: Will pharmaceutical firms increase UK-based R&D or manufacturing commits? Watch announcements in Cambridge, Oxford, and the so-called “Golden Triangle” of life sciences.

So, what do we do with this deal?

For citizens, the questions are direct and personal: do you want faster access to the newest therapies even if it means higher public spending or possible cuts elsewhere? For policymakers, the challenge is to design safeguards so that gains in access do not exacerbate health inequalities.

Trade deals are rarely simple; they are compromises written in clauses and footnotes, and their true impacts take years to register. For patients like Saira Khan’s mother, the measure of success will not be tariff codes or QALY formulas but whether a medicine changes a life.

Ask yourself: in a world where biomedicine can create miracles, what price are we willing to pay for those miracles, and who should decide?

U.S. envoy to meet Putin, seek steps to end Ukraine war

By

hanad

-

December 2, 2025

US envoy to meet Putin for talks on ending war in Ukraine — Steve Witkoff is due to meet the Russian president in

At the Kremlin Gates: A Quiet, Tense Pause Before the Next Move

The winter light on Moscow’s domes is thin and patient, as if the city itself has learned to wait out news cycles the way it waits out snow. But behind the gilded facades, the political theater was electric: a private plane from the United States touched down carrying Steve Witkoff, a long-time Trump envoy, and Jared Kushner, a name that still turns heads. They were coming not to sign a treaty on the spot but to test whether a battered European continent can be coaxed — or pressured — into a settlement that would rewrite the map of a nation.

It is a strange role for private emissaries: in an era of professional diplomacy, the presence of businessmen and presidential family members in the Kremlin is both theatrical and strategic. “You could feel the weight of the room change when they walked in,” said a Western diplomat who watched the first exchanges from a hotel across the river. “It’s not just symbolism. It signals a direct line to power that bypasses some usual filters.”

What’s on the Table — and Off It

The outlines of the conversation are already contentious. Moscow, blunt and unyielding, has long demanded that Ukraine forever forswear NATO membership, that Moscow keep control of Crimea and swathes of the east and south — Donbas, Zaporizhzhia, Kherson — and that Kyiv accept limits on its armed forces and protections for Russian speakers and the Russian Orthodox Church.

For Kyiv, those conditions read like surrender dressed in legalese. “We are not bargaining away the right to exist,” said a Ukrainian officer recently rotated from the front. “Peace that leaves us as a diminished state is merely a respite before more demands.”

Washington, meanwhile, has been attempting a delicate balancing act. A leaked set of U.S. draft proposals drew fury in Kyiv and across Europe for seeming to concede many of Moscow’s positions. The revelation pushed European capitals into huddles and prompted a chorus of corrective notes: a new, refined framework was discussed in Geneva, and a patchwork of counterproposals arrived from Brussels, Paris and Berlin.

Numbers That Refuse to Sleep

War, even when it is negotiated over polished tables, leaves a ledger of loss. Pro-Ukrainian maps and analysts estimate Russia controls more than 19% of Ukrainian territory — roughly 115,600 square kilometers. U.S. officials have suggested casualty figures in the broader theater of the conflict exceed 1.2 million killed or injured, a grim tally that neither Kyiv nor Moscow discloses in full.

And the maps are not static. In 2025, Russian forces reportedly advanced at the fastest pace since the initial 2022 invasion, with frontline towns such as Pokrovsk and Vovchansk changing hands amid fierce fighting. “We stood on the road and watched columns roll past,” remembers a teacher from Pokrovsk who fled her home with three children. “Everything you take for granted — schoolbooks, neighbors, the bakery — is suddenly part of a strategic calculation.”

Politics at Home: Corruption, Confidence, and Pressure

Kyiv’s bargaining position is also complicated by internal turbulence. A corruption scandal recently forced the dismissal of Andriy Yermak, the president’s chief of staff and one of Ukraine’s top negotiators. The shakeup has sent ripples through a government already under the strain of war. “It’s not just about personnel; it’s about trust,” said an independent Ukrainian political analyst in Kyiv. “Every move in negotiation needs domestic legitimacy.”

President Volodymyr Zelensky has been crisscrossing Europe — Dublin and Paris among them — pressing for guarantees that would allow Ukraine to come to talks with strength rather than desperation. In private meetings, European leaders have pondered how to provide military backing, economic resilience, and a legal framework that preserves Ukraine’s sovereignty without provocation that might escalate the fighting further.

On the Ground: Voices from Between the Lines

What does peace sound like at a front-line bakery or in a family’s living room? “My grandmother keeps asking when the sirens will stop,” a Kyiv baker told me as she kneaded dough in a shop that once hummed with tourists. “She doesn’t care about borders; she cares about whether her grandson comes home.”

Across the border, in a small market in a Russian-held town, a shopkeeper shrugged when asked about negotiations. “We want to sell apples and pay the bills like everyone else,” she said. “Politics is loud. The market is where life is quiet and stubborn.”

These small, stubborn lives — the baker’s loaves, the teacher’s schoolbooks, the shopkeeper’s apples — are the human units of calculation often absent from headline arithmetic.

What Would a Deal Look Like — And What Would It Cost?

There are pragmatic proposals being floated: a 10‑year security guarantee for Kyiv has been discussed in Washington; inverse proposals from Moscow would see NATO membership forever off the table and territorial arrangements that formalize Russian control over the areas it occupies. European states fear a punitive settlement that would normalize Russian gains and open the door to renewed exploitation of energy and mineral resources — and perhaps even a return of Moscow to elite clubs like the G8.

“The question isn’t just whether a treaty can be signed,” said an international security expert based in Brussels. “It’s whether the instruments exist to enforce it — and to ensure both sides actually live by the commitments.”

Key figures to watch: enforcement mechanisms, international peacekeeping presence, and guarantees for Ukraine’s territorial integrity.
Red lines cited by Russia: permanent neutrality for Ukraine; formal recognition of Kremlin-held territories.
Red lines cited by Kyiv: no territorial concessions that amount to permanent ceding of sovereignty.

Why This Matters to the World

What happens in these rooms in Moscow and in the corridors of power in Kyiv and Brussels reverberates far beyond the Black Sea. This is a contest over principles: the inviolability of borders, the power of international law, and whether economic interests can outweigh human cost.

There’s also a practical geopolitical calculus. A settlement that rewards conquest could reshape global energy markets, reconfigure alliances, and send a message: territorial expansion pays. Conversely, a settlement that restores Ukraine’s control could embolden smaller states to resist coercion, but might leave Europe shouldering a long, costly security commitment.

Questions to Carry Home

As readers, what should we expect? Should a war-weary world prize an imperfect peace now, or insist on hard terms and risk more bloodshed? If you were at the negotiating table, whose future would you think of first — the soldier who might be able to return home tomorrow, or the generations who would inherit a truncated, humiliated state?

In the end, the human scenes — the empty chairs at school desks, the baker’s flour-dusted hands, the market’s quiet bargaining — are the true arbiters. Diplomacy is architecture; people live in its rooms. The question is not merely whether a treaty can be signed in Moscow. It’s whether the people who must live with its terms will be given a voice in the drawing of the lines.

As envoys arrive and the Kremlin prepares for another round of talks, one thought lingers: peace is not a document. Peace is a sequence of choices, large and small. The world is watching to see which choices are made, and who gets to tell the story afterward.

Go’aan cusub oo ka dhan ah Soomaalida ku nool Minnesota oo soo baxay

By

aden

-

December 2, 2025

Dec 02(Jowhar)-Maamulka Trump, wuxuu maanta ku dhawaaqay inay billaabayaan baaritaan la xiriira canshuurta gobolka Minnesota oo la musuq maasuqay inay gaartay ururka al-Shabaab ee Soomaaliya , sida uu shaaciyay xoghayaha maaliyadda Mareykanka,Scott Bessent.

Continue

WHO endorses anti-obesity medications to combat the global obesity crisis

By

hanad

-

December 2, 2025

WHO backs weight-loss drugs to tackle obesity epidemic — Appetite-suppressing drugs, including blockbuster brands Ozempic and Mounjaro, have become massively popular in recent years

A new weapon in a long war: what the WHO’s guidance on weight-loss drugs means for the world

On a crowded morning in Nairobi’s Kibera market, vendors call across the aisles, urging passersby to try sweet, steaming samosas and mangoes gleaming like jewels. Across the world, on a quiet clinic bench in suburban Sydney, a woman opens a small pen the size of a highlighter and prepares an injection she hopes will finally stop hunger that has felt relentless for years. These two scenes—one of abundance, one of private resolve—are connected by an unfolding global health story.

This week the World Health Organization took a decisive step into that story. For the first time, the agency issued formal guidance endorsing the use of a new class of drugs—GLP-1 receptor agonists, the family that includes household names like semaglutide (branded as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro)—as tools for treating adult obesity as a chronic, relapsing condition.

Why this matters now

The timing is wrenching: more than one billion people live with obesity worldwide, according to WHO estimates, and in 2022 roughly 3.7 million deaths were linked to conditions caused or worsened by excess weight—more than the toll from malaria, tuberculosis and HIV combined. If current trends continue, WHO warns, the number of people living with obesity could double by 2030.

“We often talk about epidemics in terms of viruses,” said Dr. Elena Vargas, an epidemiologist who has worked in community health programs across Latin America. “But obesity behaves differently: it’s baked into our food systems, our workplaces, our cities. These new medicines are powerful, but they don’t change the economic and social forces that pushed us here.”

What the guidance says—and what it doesn’t

WHO’s guidance frames GLP-1 therapies as part of long-term, person-centered care for adults, excluding pregnant women, and urges they be combined with behavioral support—nutrition counseling, exercise programs, and social interventions—rather than used in isolation.

“This guidance recognises obesity as a chronic disease needing comprehensive care,” said a WHO statement accompanying the release. “Medication alone will not solve the crisis, but GLP-1 therapies can help millions reduce weight and the harms associated with it.”

That’s a measured line. Researchers are excited because clinical trials show dramatic results: many patients lose significant weight and see improvements in blood sugar, blood pressure, and cholesterol. But the long-term safety profile beyond a few years, and the best ways to combine drugs with community-level prevention, remain open questions.

Lives in the balance: personal stories and global implications

In Manila, 42-year-old Maria Santos said a GLP-1 prescription gave her the first sustained relief from crushing appetite since her twenties. “For the first time in years, I could walk up the stairs without thinking about my breath or my knees,” she told me in a phone call. “But the pharmacist warned me it’s expensive. If I stop, I worry the weight will return.”

Her fear captures a central dilemma: these drugs can be transformational, but evidence and experience suggest many people need prolonged—or even lifelong—treatment to sustain benefits. And prolonging access requires money, distribution systems, and political will.

Globally, the economic stakes are staggering. WHO estimates the cost of obesity to the global economy could reach $3 trillion annually by the end of this decade—straining health systems, shrinking productivity and deepening inequalities. If GLP-1 drugs can prevent diabetes, heart attacks and cancer in some, the savings could be enormous. But who gains those savings depends on who gets the medicine.

Access, price, and the ethics of scarcity

The very popularity of GLP-1 drugs has created shortages that hurt people with type 1 and type 2 diabetes who rely on related medicines. High prices have quickly made these treatments out of reach for many countries where the burden of obesity and its complications is highest.

“We cannot let innovation deepen inequity,” said Jeremy Mburu, a public health advocate working in East Africa. “If these therapies remain a luxury, middle- and low-income countries will be left behind while richer populations get healthier. That would be a moral failure.”

WHO has already taken an unusual step: adding GLP-1 drugs to its Model List of Essential Medicines, a signal to governments and manufacturers that affordable versions should be prioritized. The agency urged the creation and scaling of low-cost generics to expand access in poorer nations.

Pharmaceutical pricing, patents, and intellectual property rules sit at the heart of the debate. Some countries have tools—like voluntary licensing or compulsory licensing in public health emergencies—that could lower costs. Others lack bargaining power to negotiate bulk prices or to invest in local production.

Beyond the pill: why policy matters

For all the excitement around medications, the WHO guidance returns again and again to one central idea: medication is a tool, not a cure-all. The agency calls for “intensive behavioural interventions” and population-level policies to create healthier environments—measures that might feel mundane, but can be transformative over time.

Consider simple policy levers: taxes on sugary drinks and junk food, restrictions on advertising to children, urban planning that makes walking and cycling safe and attractive, and subsidies that make fruits and vegetables cheaper than processed snacks. In cities like Copenhagen and Bogotá, investments in bike lanes and public transit have quietly reshaped daily life. In Mexico, soda taxes have nudged consumption down. These are not silver bullets, but they change the context in which individual choices are made.

“We need a portfolio approach—medicine for those who need it, and system change that prevents others from becoming sick in the first place,” said Francesca Leone, a public-health policy researcher in Rome. “Otherwise we will be medicating around the edges of a broken system.”

Questions we must ask

As readers, as patients, as taxpayers, what should we expect from our governments and pharmaceutical firms? Who should decide who gets a scarce treatment when demand outstrips supply? How do we weigh the benefits to individuals against the need to change the environments that produce poor health in the first place?

These are not academic questions. They will determine whether the coming decade bends the curve of the obesity epidemic or merely cements a two-tiered system where the wealthy access life-changing therapies and the rest shoulder the load of preventable disease.

Looking forward: a cautious optimism

There is reason for guarded hope. Medical innovation has changed health outcomes before—from antiretroviral therapy for HIV to new vaccines that slashed childhood deaths. GLP-1 therapies could be another such turning point, provided societies pair them with the kind of political and economic decisions that spread benefits widely.

“Imagine a city where sugary drinks are a treat, where walking to work is safe, and where a person with obesity can get treatment without losing their house,” Dr. Vargas said. “That is not utopia—that’s policy. The drugs are a lever. What we do with them will define the next generation.”

So where do we go from here? The WHO’s guidance is not an endpoint—it’s an invitation to reframe obesity as a chronic condition deserving sustained investment, careful regulation, and global solidarity. The question now is whether the world will answer it with the urgency, fairness and imagination the crisis demands.

Suspects Arrested After Hong Kong Fire Leaves 151 Fatalities

By

hanad

-

December 2, 2025

Suspects arrested as Hong Kong fire death toll hits 151 — People leave flowers outside the Wang Fuk Court apartment blocks in the aftermath of the deadly fire in Hong Kong's Tai Po district

Smoke over Tai Po: Hong Kong’s Shock and a City Searching for Answers

There are scenes that lodge under your skin: the metallic scent of spent smoke, bouquets of lilies bending under the weight of condolence notes, and the endless columns of emergency tape that slice through a neighborhood once known for its morning markets and children’s laughter. In Tai Po’s Wang Fuk Court, those images are now the city’s newest, most painful memory.

Last week’s inferno, which authorities now say has claimed at least 151 lives, has left an entire community wrestling with grief and a city grappling with questions about how a blaze could move so fast through a cluster of high-rise homes. “We cannot rule out the possibility of this number increasing further,” police spokesperson Tsang Shuk-yin told reporters, her words folded into the hush that fell over Hong Kong as families waited for news.

From Renovation to Catastrophe: The Materials at the Center of an Investigation

Investigators have converged on a troubling detail: the renovation work underway around the estate. Polystyrene panels, bamboo scaffolding and exterior netting—materials that are cheap and familiar on construction sites across the city—are now under intense scrutiny. Officials say seven out of 20 samples of the scaffolding netting failed fire-resistance tests, and questions swirl around whether a combination of combustible cladding and flammable protective sheeting helped a single spark become a raging blaze.

“That kind of material can act like tinder in a high-rise canyon,” explained Dr. Mei-Lin Chan, a fire-safety engineer who has advised local councils across Asia for two decades. “When you stack buildings so close and you have vertical surfaces covered in untested panels or netting, you create a pathway. Heat rises; flames leap. It’s a perfect storm of density and vulnerability.”

Arrests, Accountability, and the Hard Task of Naming Blame

As the city tries to understand how the tragedy unfolded, law enforcement has moved swiftly. Authorities have arrested 13 people on suspicion of manslaughter—12 men and one woman, aged between 40 and 77—while searches have been completed in five of the estate’s eight blocks. Chan Tung, director of crime and security for the Hong Kong Police Force, said the arrests are part of a broad effort to determine responsibility.

But the net of accountability has not only caught contractors and construction supervisors. Police also detained three people under sedition-related allegations after they distributed flyers demanding government accountability—an action that has sparked debate about space for dissent in a city still adjusting to a tightened security landscape. One of those detained, 24-year-old student Miles Kwan, was seen leaving a police station but declined to comment.

“There are two tragedies happening here,” said an older woman who refused to give her name as she laid flowers at a makeshift shrine. “The fire killed our neighbors, yes. But if people are afraid to ask why it happened, that fear kills trust too.”

What Officials Are Saying

Police spokesman Tsang Shuk-yin confirmed the death toll of 151 and warned the number could rise.
Chief Secretary Eric Chan announced that seven of 20 netting samples failed to meet fire-resistance standards.
Security chief Chris Tang framed certain online comments and leaflets as threats to national security, saying authorities must act.

Scenes of Mourning and a City in Collective Grief

Thousands have visited Wang Fuk Court over a three-day mourning period. They leave flowers, teddy bears, and handwritten notes—some simply “Rest in peace,” others asking pointedly, “Who is responsible?” The notes become a ledger of grief and growing civic unease.

At a corner stall that sells tea eggs and instant noodles, shopkeeper Mrs. Leung wiped her hands on a towel and spoke of neighbors she’d known for decades. “They called me by my nickname, ‘Ah Leung’. We shared food. They watched my grandson when I worked late,” she said, voice thick. “The estate was ordinary. That’s what makes it worse. Ordinary people, suddenly gone.”

Evidence, Ashes, and the Grim Reality of the Search

Police have found human remains inside apartment units, in hallways and on staircases. Some bodies have been reduced to ashes, investigators say, which complicates identification and deepens the anguish of families waiting for closure. “We are searching methodically, but this is painstaking, emotional work,” said one investigator, who asked not to be named.

For the loved ones still hoping for good news, the waiting is a form of agony. For others, the discovery of charred remains has confirmed their worst fears. A neighbor, Mr. Ho, recalled banging on doors and yelling for people to wake up. “I pulled my wife out. We were lucky. But many weren’t,” he said, his hands clenched into fists.

Bigger Questions: Urban Density, Regulation, and the Global Context

This fire is not merely a local tragedy; it is a mirror held up to many of the world’s dense, rapidly urbanizing cities. High-rise living, cost-cutting construction practices, and aging infrastructure collide in neighborhoods from Hong Kong to Mumbai to Rio. The World Health Organization and international urban-safety groups have long warned that fire risk in dense housing compounds when regulations are weak or poorly enforced.

“You can’t separate this from global trends,” Dr. Chan said. “Population concentration in cities, the race to retrofit older buildings without adequate oversight, and the use of cheaper, less-tested materials—those are universal pressure points.”

Questions for the Reader

What should safety look like in a city where space is measured in centimeters and millions share the same skyline? How do we balance affordability and safety? And when grief meets governance, who gets to tell the story of what went wrong?

What Comes Next

Investigators say their work will continue. For families in Tai Po, that means more waiting—more DNA tests, more autopsies, more legal processes. For a broader public, it means a renewed scrutiny of building practices, municipal oversight, and the political context in which questions of accountability are asked and, sometimes, stifled.

“We will demand answers,” said a community organizer who is helping relatives navigate the aftermath. “Not out of malice, but out of duty. If we don’t know why this happened, how can we prevent the next one?”

In the days ahead, Hong Kong will grieve, investigate, and perhaps legislate. For now, the city stands with a ribbon of lamplight, bouquets, and the slow, stubborn work of piecing together what remains—both of the buildings and of the lives that were housed inside them.